Education
About Us
Working with TipRanks
Follow Us
CVS Health Corp (CVS)
NYSE:CVS
CVS Analyst Ratings
Strong Buy
17 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CVS Stock 12 Month Forecast
Average Price Target
$73.44
▲(8.69% Upside)
| Highest Price Target$81.00 | Average Price Target$73.44 | Lowest Price Target$59.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
Reiterated
03/21/25
Wells Fargo
Reiterated
03/20/25
Mizuho Securities
Reiterated
03/14/25
Evercore ISI
Reiterated
03/12/25
Bank of America Securities
Reiterated
03/10/25
Leerink Partners
Reiterated
02/24/25
Bernstein
Reiterated
02/20/25
Cantor Fitzgerald
Reiterated
02/19/25
J.P. Morgan
Reiterated
02/18/25
Raymond James
Reiterated
02/18/25
TD Cowen
$80
Buy
18.40%
Upside
Reiterated
02/17/25
Optimistic Growth Potential for CVS Health: Charles Rhyee's Buy Rating Backed by Conservative Targets and Strong Segment PerformanceWe now est. 2025 adj. EPS of $5.97, within mgmt.'s guide of $5.75-$6.00. We est. HCB MBR of 91.6% (vs. guide of 91.5% at low end), and HSS adj. op. inc. $7.58B (vs. guide of "at least $7.54B"). We continue to view mgmt.'s '25 targets as conservative, particularly assumptions around trend remaining elevated trend throughout '25 and PBM growth of just 5% (w/ IRA PDP and strong spec. trends). Model Update We update our CVS estimates following 4Q results, where mgmt. introduced 2025 targets (adj. EPS of at $5.75-$6.00). We now est. 2025 adj. EPS of $5.97, and assume 55% of adj. EPS occurs in 1H.
Deutsche Bank
$66→$70
Buy
3.60%
Upside
Reiterated
02/14/25
CVS Health price target raised to $70 from $66 at Deutsche BankCVS Health price target raised to $70 from $66 at Deutsche Bank
Argus Research
$77
Buy
13.96%
Upside
Reiterated
02/14/25
Argus Research Sticks to Its Buy Rating for CVS Health (CVS)We are raising our target price on BUY-rated CVS Health Corp. (NYSE: CVS) to $77 from $68. Despite an uneven performance over the past few years, we think CVS remains well positioned to capitalize on favor- able demand trends for healthcare from an aging U.S. population, and to help to bring down rising health care costs that have pressured consumers, providers, and government payers alike. CVS recently estimated that its business assets have a reach of 185 million Americans.
Morgan Stanley
$63→$68
Buy
0.64%
Upside
Reiterated
02/13/25
Buy Rating for CVS Health Amid Fiscal Year 2025 Guidance and Medicare Advantage Turnaround Prospects
Truist Financial
$60→$76
Buy
12.48%
Upside
Reiterated
02/13/25
Truist Financial Reaffirms Their Buy Rating on CVS Health (CVS)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
Reiterated
03/21/25
Wells Fargo
Reiterated
03/20/25
Mizuho Securities
Reiterated
03/14/25
Evercore ISI
Reiterated
03/12/25
Bank of America Securities
Reiterated
03/10/25
Leerink Partners
Reiterated
02/24/25
Bernstein
Reiterated
02/20/25
Cantor Fitzgerald
Reiterated
02/19/25
J.P. Morgan
Reiterated
02/18/25
Raymond James
Reiterated
02/18/25
TD Cowen
$80
Buy
18.40%
Upside
Reiterated
02/17/25
Optimistic Growth Potential for CVS Health: Charles Rhyee's Buy Rating Backed by Conservative Targets and Strong Segment PerformanceWe now est. 2025 adj. EPS of $5.97, within mgmt.'s guide of $5.75-$6.00. We est. HCB MBR of 91.6% (vs. guide of 91.5% at low end), and HSS adj. op. inc. $7.58B (vs. guide of "at least $7.54B"). We continue to view mgmt.'s '25 targets as conservative, particularly assumptions around trend remaining elevated trend throughout '25 and PBM growth of just 5% (w/ IRA PDP and strong spec. trends). Model Update We update our CVS estimates following 4Q results, where mgmt. introduced 2025 targets (adj. EPS of at $5.75-$6.00). We now est. 2025 adj. EPS of $5.97, and assume 55% of adj. EPS occurs in 1H.
Deutsche Bank
$66→$70
Buy
3.60%
Upside
Reiterated
02/14/25
CVS Health price target raised to $70 from $66 at Deutsche BankCVS Health price target raised to $70 from $66 at Deutsche Bank
Argus Research
$77
Buy
13.96%
Upside
Reiterated
02/14/25
Argus Research Sticks to Its Buy Rating for CVS Health (CVS)We are raising our target price on BUY-rated CVS Health Corp. (NYSE: CVS) to $77 from $68. Despite an uneven performance over the past few years, we think CVS remains well positioned to capitalize on favor- able demand trends for healthcare from an aging U.S. population, and to help to bring down rising health care costs that have pressured consumers, providers, and government payers alike. CVS recently estimated that its business assets have a reach of 185 million Americans.
Morgan Stanley
$63→$68
Buy
0.64%
Upside
Reiterated
02/13/25
Buy Rating for CVS Health Amid Fiscal Year 2025 Guidance and Medicare Advantage Turnaround Prospects
Truist Financial
$60→$76
Buy
12.48%
Upside
Reiterated
02/13/25
Truist Financial Reaffirms Their Buy Rating on CVS Health (CVS)
Best Analysts Covering CVS Health
Which Analyst Should I Follow If I Want to Buy CVS and Sell After:
1 Month
xxx
Success Rate
19/28 ratings generated profit
Average Return
+1.43%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 67.86% of your transactions generating a profit, with an average return of +1.43% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
Average Return
+6.16%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +6.16% per trade.
1 Year
Success Rate
11/17 ratings generated profit
Average Return
+8.24%
reiterated a buy rating 14 days ago
Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +8.24% per trade.
2 Years
xxx
Success Rate
15/21 ratings generated profit
Average Return
+15.32%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +15.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CVS Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
2
4
4
2
Buy
35
39
30
29
30
Hold
11
12
11
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
53
45
40
36
Each month's total comprises the sum of three months' worth of ratings.
CVS Financial Forecast
CVS Stock Forecast FAQ
What is CVS’s average 12-month price target, according to analysts?
Based on analyst ratings, CVS Health Corp’s 12-month average price target is $73.44.
What is CVS’s upside potential, based on the analysts’ average price target?
CVS Health Corp has 8.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CVS a Buy, Sell or Hold?
CVS Health Corp has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
What is CVS Health Corp’s price target?
The average price target for CVS Health Corp is $73.44. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $81.00 ,the lowest forecast is $59.00. The average price target represents 8.69% Increase from the current price of $67.57.
The highest analyst price target is $81.00 ,the lowest forecast is $59.00. The average price target represents 8.69% Increase from the current price of $67.57.
What do analysts say about CVS Health Corp?
CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of CVS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.